UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1)

Diabetic medicine, 2014-02, Vol.31 (2), p.176-184

2014

Volltextzugriff (PDF)

Diabetes and breast cancer risk: a meta-analysis

Breast cancer research and treatment, 2012-10, Vol.107 (9), p.1608-1617

2012

Volltextzugriff (PDF)

Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus

Diabetes & metabolism, 2013-12, Vol.39 (6), p.485-496

2013

Volltextzugriff (PDF)

Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial

Diabetic medicine, 2006-02, Vol.23 (2), p.141-147

2006

Volltextzugriff (PDF)

Lixisenatide, a novel GLP-1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus

Diabetes, obesity & metabolism, 2014-07, Vol.16 (7), p.588-601

2014

Volltextzugriff (PDF)

Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin

Diabetic medicine, 2004-11, Vol.21 (11), p.1213-1220

2004

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro

Diabetes (New York, N.Y.), 2000-12, Vol.49 (12), p.2142-2148

2000

Volltextzugriff (PDF)

Insulin analogues and their potential in the management of diabetes mellitus

Diabetologia, 1999-10, Vol.42 (10), p.1151-1167

1999

Volltextzugriff (PDF)

New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)

Diabetes, obesity & metabolism, 2015-04, Vol.17 (4), p.386-394

2015

Volltextzugriff (PDF)

Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes

Diabetes, obesity & metabolism, 2015-09, Vol.17 (9), p.859-867

2015

Volltextzugriff (PDF)

New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2)

Diabetes, obesity & metabolism, 2016-04, Vol.18 (4), p.366-374

2016

Volltextzugriff (PDF)

A direct comparison of long- and short-acting GLP-1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatment

Diabetes, obesity & metabolism, 2014-02, Vol.16 (2), p.170-178

2014

Volltextzugriff (PDF)

New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1)

Diabetes, obesity & metabolism, 2016-04, Vol.18 (4), p.375-383

2016

Volltextzugriff (PDF)

Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension

Diabetes, obesity & metabolism, 2015-12, Vol.17 (12), p.1142-1149

2015

Volltextzugriff (PDF)

One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension

Diabetes, obesity & metabolism, 2015-09, Vol.17 (9), p.835-842

2015

Volltextzugriff (PDF)

Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL compared with glargine 100 U/mL in Japanese adults with type 2 diabetes using basal insulin plus oral anti-hyperglycaemic drugs (EDITION JP 2 randomised 12-month trial including 6-month extension)

Diabetes & metabolism, 2017-10, Vol.43 (5), p.446-452

2017

Volltextzugriff (PDF)

Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL versus glargine 100 U/mL: A patient-level meta-analysis examining older and younger adults with type 2 diabetes

Diabetes & metabolism, 2020-04, Vol.46 (2), p.110-118

2020

Volltextzugriff (PDF)

Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) – a review of evidence and clinical interpretation

Diabetes & metabolism, 2019-09, Vol.45 (4), p.330-340

2019

Volltextzugriff (PDF)

Effects of whole-body vibration exercise on the endocrine system of healthy men

Journal of endocrinological investigation, 2004-04, Vol.27 (4), p.323-327

2004

Volltextzugriff (PDF)

GLP-1 RAs as compared to prandial insulin after failure of basal insulin in type 2 diabetes: lessons from the 4B and Get-Goal DUO 2 trials

Diabetes & metabolism, 2015-12, Vol.41 (6), p.6S16-6S20

2015

Volltextzugriff (PDF)

Effect of the amino acid alanine on glucagon secretion in non-diabetic and type 1 diabetic subjects during hyperinsulinaemic euglycaemia, hypoglycaemia and post-hypoglycaemic hyperglycaemia

Diabetologia, 2007-02, Vol.50 (2), p.422-430

2007

Volltextzugriff (PDF)

Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime

Diabetes care, 1999-03, Vol.22 (3), p.468-477

1999

Volltextzugriff (PDF)

Italian Titration Approach Study (ITAS) with insulin glargine 300 U/mL in insulin-naïve type 2 diabetes: Design and population

Nutrition, metabolism, and cardiovascular diseases, 2019-05, Vol.29 (5), p.496-503

2019

Volltextzugriff (PDF)

The new long-acting insulin glargine U300 achieves an early steady state with low risk of accumulation

Diabetes & metabolism, 2016-04, Vol.42 (2), p.77-79

2016

Volltextzugriff (PDF)

Use of the short-acting insulin analogue lispro in intensive treatment of Type 1 diabetes mellitus: importance of appropriate replacement of basal insulin and time-interval injection-meal

Diabetic medicine, 1998-07, Vol.15 (7), p.592-600

1998

Volltextzugriff (PDF)

1 – 25 von 405

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(346)
Mit Volltextzugriff
(298)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(265)
Life Sciences & Biomedicine
(258)
Humans
(250)
Male
(156)
Biological And Medical Sciences
(150)
Endocrinology & Metabolism
(150)
Female
(149)
Adult
(134)
Medical Sciences
(134)
Middle Aged
(101)
Blood Glucose - Metabolism
(84)
Insulin
(71)
Endocrinopathies
(68)
Endocrine Pancreas. Apud Cells
(63)
Diabetes
(61)
Insulin - Blood
(59)
Diabetes. Impaired Glucose Tolerance
(58)
Cardiovascular System & Cardiology
(53)
Insulin - Administration & Dosage
(50)
Diabetes Mellitus, Type 1 - Drug Therapy
(48)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1)

Diabetes and breast cancer risk: a meta-analysis

Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus

Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial

Lixisenatide, a novel GLP-1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus

Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro

Insulin analogues and their potential in the management of diabetes mellitus

New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)

Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes

New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2)

A direct comparison of long- and short-acting GLP-1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatment

New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1)

Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension

One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension

Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL compared with glargine 100 U/mL in Japanese adults with type 2 diabetes using basal insulin plus oral anti-hyperglycaemic drugs (EDITION JP 2 randomised 12-month trial including 6-month extension)

Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL versus glargine 100 U/mL: A patient-level meta-analysis examining older and younger adults with type 2 diabetes

Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) – a review of evidence and clinical interpretation

Effects of whole-body vibration exercise on the endocrine system of healthy men

GLP-1 RAs as compared to prandial insulin after failure of basal insulin in type 2 diabetes: lessons from the 4B and Get-Goal DUO 2 trials

Effect of the amino acid alanine on glucagon secretion in non-diabetic and type 1 diabetic subjects during hyperinsulinaemic euglycaemia, hypoglycaemia and post-hypoglycaemic hyperglycaemia

Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime

Italian Titration Approach Study (ITAS) with insulin glargine 300 U/mL in insulin-naïve type 2 diabetes: Design and population

The new long-acting insulin glargine U300 achieves an early steady state with low risk of accumulation

Use of the short-acting insulin analogue lispro in intensive treatment of Type 1 diabetes mellitus: importance of appropriate replacement of basal insulin and time-interval injection-meal

Suchergebnisse filtern